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We report a case of multiple autoimmunity consisting of the presence of autoimmune haemolytic anaemia (AIHA), antimi-
tochondrial antibodies (AMAs), and antiphospholipid antibodies (APLAbs) as the presenting manifestations of an extrahepatic
B-non-Hodgkin lymphoma (B-NHL) in a 63-year-old woman. The patient presented with fatigue attributed to severe AIHA. Due
to increased serum IgM and γ-GT levels, an investigation for AMA was performed, which proved positive with anti-M2 speciﬁcity.
A prolongation of activated partial thromboplastin time (aPTT) led to the determination of APLAbs (lupus anticoagulant and
other APLAbs) which were also positive. Bone marrow biopsy in combination with immmunohistochemical studies established
thediagnosisoflymphoplasmacyticB-NHL.Tenmonthslater,B-NHLwasinremissionwhileAMAandAPLAbswerestillpositive.
In conclusion, we documented the coexistence of multiple autoimmune reactions together with B-NHL highlighting the possible
common pathogenetic pathways of the two entities.
1.Introduction
Lymphoproliferative disorders include several well-recogni-
zed disease entities, deﬁned by diﬀerent cell origin, pathol-
ogy, and prognosis. Immune dysregulation is thought to play
a major role in lymphomagenesis as attested by the increased
risk of certain lymphomas following organ transplantation,
infections, immunodeﬁciency states, and autoimmune dis-
eases or syndromes [1–3].
On the other hand, autoimmune diseases comprise a
broad variety of conditions characterized by dysregulation
of the immune response leading to the loss of tolerance to
self-antigens. Diverse associations between malignancy and
autoimmunity have been shown in multiple levels [2, 4]. In
particular, the association between lymphomas and autoim-
munity is well known several years ago, starting by obser-
vations that autoimmunity is often present in patients with
non-Hodgkin lymphoma (NHL), mouse strains showing
association between autoimmune disease and lymphoma,
and epidemiologic evidence that autoimmune disorders
carry a signiﬁcantly increased risk of NHL development
compared to healthy population [1, 5, 6]. Exploring the
pathogenetic mechanisms of this association, recent data
show that they might be bi-directional [7–9].
However, autoimmune rheumatic features and/or autoi-
mmune phenomena occur frequently in the course of lymp-
hoproliferative malignancies, and they may sometimes be
the ﬁrst sign of the malignancy [7]. However, to the best
of our knowledge, multiple autoimmunity consisting of
the presence of autoimmune haemolytic anaemia (AIHA),
antimitochondrial antibodies (AMAs), and antiphospho-
lipid antibodies (APLAbs) as the presenting manifestations
of an extrahepatic B-NHL has not been previously described
so far. Therefore, a representative case is reported herein,
with an appropriate and extensive review of the literature.
2.CaseReport
A 63-year-old woman was admitted to our department
because of fatigue, weakness and dysesthesias (numbness) of2 Autoimmune Diseases
thelowerlimbsduringthelasttwomonthsbutwithoutfever.
Physical examination revealed paleness, mild jaundice, and
splenomegaly but no palpable peripheral lymph nodes and
no neurological ﬁndings. Her family and past history were
unrevealing.
Laboratory tests revealed severe anaemia, increased retic-
ulocytecount,andelevatedserumlevelsofindirectbilirubin,
gamma-glutamyl-transpeptidase (γ-GT), immunoglobulin
M (IgM), and lactate dehydrogenase (LDH) (Table 1).
The white blood cells (WBCs) and platelets (PLT) counts
were within normal limits. Peripheral blood smear showed
spherocytes and polychromatic red cells consistent with
haemolysis. Direct and indirect Coombs’ tests were positive
forimmunoglobulinG(IgG)speciﬁcity,whileamarkedpro-
longation of activated partial thromboplastin time (aPTT)
was obvious (Table 1). Accordingly, a diagnosis of AIHA was
made.
The presence of increased IgM levels in a female patient,
along with the elevation of γ-GT on several occasions,
prompted us to investigate for the presence of antimitochon-
drial autoantibodies (AMA), the hallmark for the diagnosis
of primary biliary cirrhosis (PBC) [10]. Liver autoimmune
serology detected AMA (titre 1/320; positive titre >1/20) by
indirect immunoﬂuorescence (IIF) on in-house rat multior-
gan substrate panel that included kidney, liver, and stomach
as we published previously using standard protocols [10].
T h eA M A sw e r ea l s od e t e c t e dt w i c eb ya ne n h a n c e dp e r f o r -
mance M2 IgG-isotype-speciﬁc ELISA (30 units; UNL: 20
units) according to the manufacturer’s instructions (ELISA;
QuantaLite,INOVADiagnostics,SanDiego,Calif,USA)and
blotting using rat liver mitochondrial fractions [10–12]. Due
totheprolongationofaPTT(Table 1),investigationforlupus
anticoagulant (LA), anticardiolipin antibodies (aCLAbs),
and antibodies against β2-glycoprotein I (anti-β2-GPI) of
IgM and IgG speciﬁcity was done, which revealed high
positivity for APLAbs in two occasions (Table 1), at least 12
weeks apart, as dictated by the revised classiﬁcation criteria
for the diagnosis of antiphospholipid syndrome (APLS)
[13, 14]. Due to the above-mentioned ﬁndings as well as
to the severity of AIHA, liver biopsy at this time point was
considered unethical and was not performed.
Infact,bothIgMandIgGaCLAbsaswellasIgManti-β2-
GPI Abs were positive (Table 1; ELISAs, INOVA Diagnostics,
San Diego, Calif USA; cut-oﬀs: 20 units).
A total-body computed tomography did not show
abdominal or mediastinal lymphadenopathy. Serum protein
electrophoresis and subsequent immunoﬁxation revealed
a monoclonal IgM light chain while bone marrow biopsy
in combination with immmunohistochemical studies
established the diagnosis of lymphoplasmacytic B-NHL
(Figure 1).
Prednisolone (1mg/kg/day) was started, and after a six-
week course, haemoglobin, reticulocytes, and LDH levels
had already become normal (Table 1). In addition, till
the time of this writing, the patient has received three
cycles of chemotherapy every 28 days (500mg rituximab,
2mg bortezomib, and 16mg dexamethazone). There was a
marked clinical and laboratory improvement with absence
of splenomegaly and decrease of IgM serum concentration
(a)
(b)
(c)
Figure 1: Bone marrow biopsy: Inﬁltration by lymphoplasmacytic
B-NHL. Hematoxylin-eosin staining (a). Immunohistochemical
staining for anti-CD20 (b) and anti-CD 138 (c).
(Table 1) During the whole follow-up period (10 months),
no thrombotic complication or development of clinical
manifestations of PBC was noted though AMA and APLAbs
remained steadily positive (Table 1).
3. Discussion
To the best of our knowledge, we describe herein for the ﬁrst
time the simultaneous detection of AMA and APLAbs in a
patient with AIHA on the ground of systemic B-NHL.
The presence of AMA with anti-M2 antibody speciﬁcity
is the major hallmark for the diagnosis of PBC [10, 15].
Actually, PBC diagnosis is usually based on the presence
of at least 2 out of 3 of the following criteria: elevation of
cholestatic enzymes, positive titre of AMA (titre≥1/40), and
characteristic liver biopsy [10, 15–17]. Clinically, the disease
has a combination of characteristic symptoms including
pruritus and profound fatigue though asymptomatic cases at
the time of diagnosis are not infrequent as it is well knownAutoimmune Diseases 3
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that even an isolated AMA positive test is indicative of early
PBC and that silent disease eventually becomes clinically
and biochemically evident up to 18 years after the ﬁrst
AMA screening [16–19]. In our case, the stable presence of
AMA during followup rather excluded false positive serology
during the acute setting of AIHA. However, it is not known
whether PBC preceded NHL since they were diagnosed
simultaneously.
Conﬂicting evidence exists regarding the association
between PBC and NHL, while the presence of AMA without
any clinical sign of liver disease, in patients with hemato-
logic malignancies, has also been reported [6]. There are
also several case reports linking PBC with NHL especially
of the primary hepatic type [20–22]. However, a recent
retrospective study by Panjala et al. [23] failed to conﬁrm
such an association since the estimated baseline risk of
lymphoma in 2912 patients with PBC was as low as <1%.
Of note, the latter study showed that disease involvement
was predominately extrahepatic, above the diaphragm [23].
There are also case reports of splenic lymphoma with hepatic
inﬁltration presented as AMA-positive PBC [24]. However,
neither the prevalence nor the clinical signiﬁcance of AMA
in hematologic malignancies with liver involvement has been
estimated in large series.
APLAbs have been frequently associated with NHL as
well as PBC [25, 26]. Their prevalence in patients with NHL
varies from 26.6% to 41% [25, 27]. The pathogenicity of
APLAbs in malignancy and in particular in NHL is not
very clear: they do not seem to correlate with thrombotic
events or other clinical manifestations of the APLS [25, 28],
thoughthromboticeventsassociatedwithAPLAbscanbethe
ﬁrst manifestation of malignancy including NHL [29], while
APLAbs have been suggested as independent prognostic
factorsincaseswithaggressiveNHL[27].Ontheotherhand,
IgM and/or IgG aCLAbs have been detected in up to 40%
of patients with PBC; they were associated with more severe
disease, but they rather seem to be “nonpathogenic or non-
thrombogenic” (anti-β2-GPI-independent) [25]. However,
our patient was also IgM anti-β2-GPI Abs positive which
means that the IgM aCLAbs were potentially “pathogenic or
thrombogenic” (co-factor dependent), and therefore, a close
followup for any clinical manifestation of the APLS seems
mandatory.
Finally, it is well known that AIHA is highly associated
with lymphoproliferative disorders [1, 5–7]. This frequent
and close association makes the exclusion of lymphoprolif-
erative disorders essential when AIHA is diagnosed [1, 5–7].
On the contrary, one of the many extrahepatic autoimmune
manifestations that PBC has been linked to is AIHA, mainly
in case reports [30–32].
Overall, all the above-mentioned data indicate that, in
our patient, it is not clear whether the multiple autoimmune
reactions with the simultaneous detection of APLAbs, AIHA,
andAMAisthecauseortheeﬀectoftheunderlyinglympho-
proliferative disorder. Goodnow [33] described the pathways
and genes likely to be involved in both autoimmune diseases
and lymphomas, emphasizing that both types of diseases
arise as a consequence of multistep processes that eliminate
the checkpoints that inhibit uncontrolled B-cell growth,
includinguncontrolledgrowthofautoimmunelymphocytes.
The most prominent example is the ﬁnding that somatic and
germ-line Fas mutations, which presumably interfere with
apoptosis,areassociatedwithbothautoimmunediseasesand
lymphomas in mice and in humans, while B-cell-activating
factor of the TNF family (BAFF), which enhances survival of
B cells, is found to be overexpressed in Sjogren’s syndrome,
rheumatoid arthritis, systemic lupus erythematosus, and
lymphomas [34, 35].
In conclusion, our clinical case illustrates the possibility
of a common pathogenetic pathway between the loss of tol-
erance to self-antigens leading to autoimmune phenomena
and a lymphoproliferative disorder and raises, once again,
the unanswered question of which is the cause and which the
eﬀect.
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